• May 5, 2016

    Article Spotlight

    What’s in a Name? The Root of Elamipretide

    Read the full article

    According to the World Health Organization and United States Adopted Names Council (USAN), a generic, or nonproprietary, name should be simple, informative and unique, and based on pharmacological and/or chemical relationships. In 2014, Stealth BioTherapeutics began the process of securing an internationally recognized generic name for MTP-131, our investigative product for the treatment of mitochondrial… Continue Reading >

    Read the full Article
  • April 3, 2016

    Press Release Spotlight

    Stealth BioTherapeutics announces presentation of elamipretide data at ACC

    Read the full article

    BOSTON – April 3, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs for treating mitochondrial dysfunction, announced promising results from the Phase 1 PREVIEW trial evaluating elamipretide (formerly known as Bendavia) in heart failure patients with reduced ejection fraction. The results…

    Read the full Press Release
  • March 8, 2016

    Press Release Spotlight

    Stealth BioTherapeutics Initiates Phase 2 Clinical Study of Elamipretide in Fuchs’ Corneal Endothelial Dystrophy

    Read the full article

    BOSTON – March 8, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced the initiation of ReVEAL, a Phase 2 clinical study evaluating the topical eye drop formulation of elamipretide (formerly known as Ocuvia)…

    Read the full Press Release
  • March 1, 2016

    Press Release Spotlight

    Stealth BioTherapeutics to Present at Cowen & Co. 36th Annual Health Care Conference

    Read the full article

    BOSTON – March 1, 2016 – Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced that Reenie McCarthy, Chief Executive Officer of Stealth, will present at the Cowen & Co. 36th Annual Health Care Conference at 12:00 p.m. ET on Tuesday, March 8, 2016 in Boston. Stealth BioTherapeutics: Leading… Continue Reading >

    Read the full Press Release

What’s in a Name? The Root of Elamipretide

According to the World Health Organization and United States Adopted Names Council (USAN), a generic, or nonproprietary, name should be simple, informative and unique, and based on pharmacological and/or chemical relationships. In 2014, Stealth BioTherapeutics began the process of securing an internationally recognized generic name for MTP-131, our investigative product for the treatment of mitochondrial… Continue Reading >

Stealth BioTherapeutics announces presentation of elamipretide data at ACC

BOSTON – April 3, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs for treating mitochondrial dysfunction, announced promising results from the Phase 1 PREVIEW trial evaluating elamipretide (formerly known as Bendavia) in heart failure patients with reduced ejection fraction. The results…

Stealth BioTherapeutics to Present at Cowen & Co. 36th Annual Health Care Conference

BOSTON – March 1, 2016 – Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced that Reenie McCarthy, Chief Executive Officer of Stealth, will present at the Cowen & Co. 36th Annual Health Care Conference at 12:00 p.m. ET on Tuesday, March 8, 2016 in Boston. Stealth BioTherapeutics: Leading… Continue Reading >

Stealth BioTherapeutics Receives FDA Fast Track Designation for Rare Disease Indication

Potential therapeutic for primary mitochondrial myopathy associated with genetic mitochondrial disease BOSTON – January 7, 2016 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for MTP-131 (also known as Bendavia) for the treatment of… Continue Reading >